Dexcom’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...
Dexcom’s Growth Potential and Strategic Catalysts Justify Buy Rating and New Price Target
In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of ...